GlassScriptPhysician profile
Tabinda Shafiq
NPI 1477905495
$4,174.38
in general payments reported to CMS, 2019-2025
28 companies · $564 in 2025
The $564 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $166 · 2022: $859 · 2023: $1,245 · 2024: $1,341 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,149 · Education: $0.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,149.29 |
| Education | $0.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $543.75 | 2021-2025 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $408.46 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $339.53 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.84 | 2021-2025 | Jardiance |
| Insulet Corporation | $289.70 | 2022-2023 | Omnipod |
| Abbott Laboratories | $263.30 | 2024-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $231.27 | 2023-2025 | Korlym |
| Dexcom, INC. | $223.82 | 2021-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $202.40 | 2022-2025 | |
| Medtronic, INC. | $161.42 | 2022-2024 | Minimed 780g, Minimed 770g |
| Novo Nordisk INC | $152.30 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $149.62 | 2023-2024 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $133.51 | 2022-2025 | Tymlos |
| Tandem Diabetes Care, INC. | $126.39 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $124.72 | 2023-2024 | Crysvita |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $92.82 | 2021-2022 | |
| Horizon Therapeutics Plc | $80.20 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $79.03 | 2024-2025 | |
| Sequel Med Tech, LLC | $56.04 | 2025 | Twiist |
| Merck Sharp & Dohme LLC | $39.13 | 2021-2023 | Steglujan, Steglatro |
| Abbvie INC. | $33.03 | 2022 | |
| Ascendis Pharma Endocrinology INC | $29.32 | 2025 | Yorvipath |
| Nevro Corp. | $28.80 | 2023-2024 | Senza |
| Eisai INC. | $24.58 | 2021 | |
| Vivus LLC | $24.42 | 2022 | |
| Upsher-Smith Laboratories LLC | $16.67 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.75 | 2021 | |
| Beta Bionics, INC. | $13.56 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabinda Shafiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.